ConductScience.org, home

Paper26537178

Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.

Peng L and 4 others. Eur J Cancer Care (Engl), 2017. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Papers, record 26537178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26537178

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
PubMed
Journal
Eur J Cancer Care (Engl)
PubMed
Year
2017
PubMed
Publication types
Journal Article, Meta-Analysis
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
1.8
iCite
Revised in PubMed
2022-03-11
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Peng LL
2Bu ZZ
3Ye XX
4Zhou YY
5Zhao QQ

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AlbuminsMajor topic
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
PaclitaxelMajor topic
Peripheral Nervous System DiseasesMajor topic
Humans
Incidence
Risk
Severity of Illness Index
Taxoids

Source PubMed

Download CSV of topics

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
42439657Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation.Cells2026https://conductscience.org/library/papers/42439657PubMed
41840368Platinum-free triplet therapy with nab-paclitaxel, S-1, and tislelizumab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: a phase ii single-arm trial.BMC Cancer2026https://conductscience.org/library/papers/41840368PubMed
40819029Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.BMC Cancer2025https://conductscience.org/library/papers/40819029PubMed
40230322Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study.Acta Oncol2025https://conductscience.org/library/papers/40230322PubMed
39589666Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study.Discov Oncol2024https://conductscience.org/library/papers/39589666PubMed
39403794Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study.Oncologist2025https://conductscience.org/library/papers/39403794PubMed
37403746Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.Cancer Med2023https://conductscience.org/library/papers/37403746PubMed
37270638A retrospect study based on real-world data to observe metabolic function in cancer patients using albumin-bound paclitaxel.Sci Rep2023https://conductscience.org/library/papers/37270638PubMed
36675434
A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy.
J Clin Med2023https://conductscience.org/library/papers/36675434PubMed
36147633Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer.Biomed Res Int2022https://conductscience.org/library/papers/36147633PubMed
35614037Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.Cell Death Dis2022https://conductscience.org/library/papers/35614037PubMed
351410155-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity.Am J Cancer Res2022https://conductscience.org/library/papers/35141015PubMed
34655433Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncol Ther2021https://conductscience.org/library/papers/34655433PubMed
34481421Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.Basic Clin Pharmacol Toxicol2022https://conductscience.org/library/papers/34481421PubMed
33922821Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas.J Clin Med2021https://conductscience.org/library/papers/33922821PubMed
33671327Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.Int J Mol Sci2021https://conductscience.org/library/papers/33671327PubMed
33445874The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chem Rev2021https://conductscience.org/library/papers/33445874PubMed
33370027Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.Pancreas2021https://conductscience.org/library/papers/33370027PubMed
31901783Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.Breast2020https://conductscience.org/library/papers/31901783PubMed
31592123Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.Adv Sci (Weinh)2019https://conductscience.org/library/papers/31592123PubMed

See all 29 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26537178

GET https://conductscience.org/api/papers/v1/26537178/cited_by?page=2